ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study — Activities of Daily Living, Mild Cognitive Impairment)
📖 Wiki Page
scale615 wordssynced 2026-04-02
Type: Informant-rated functional outcome measure
Purpose: Assess ability to perform daily activities in mild cognitive impairment and early Alzheimer's disease
Developer: Galasko et al., Alzheimer's Disease Cooperative Study (ADCS)[@galasko1997]
Current use: Co-primary endpoint in LY-3372689 MAGNOLIA trial, and most early AD therapeutic trials
Overview
...
Type: Informant-rated functional outcome measure
Purpose: Assess ability to perform daily activities in mild cognitive impairment and early Alzheimer's disease
Developer: Galasko et al., Alzheimer's Disease Cooperative Study (ADCS)[@galasko1997]
Current use: Co-primary endpoint in LY-3372689 MAGNOLIA trial, and most early AD therapeutic trials
Overview
Mermaid diagram (expand to render)
The ADCS-MCI-ADL is a 24-item informant-rated scale developed by the Alzheimer's Disease Cooperative Study to assess functional abilities in patients with mild cognitive impairment["@galasko1997"]. Unlike performance-based cognitive tests, this scale relies on an informant (caregiver, family member) who observes the patient's daily functioning over time.
The scale was specifically designed for MCI populations where functional impairment is subtle but clinically meaningful. It captures the early loss of instrumental activities of daily living (IADLs) that distinguishes MCI from normal aging["@petersen2004"]. The ADCS-MCI-ADL has become the standard functional co-primary endpoint in early AD trials, typically paired with [ADAS-Cog](/entities/adas-cog) as the cognitive co-primary.